Order Book (Existing Plant FY27)
₹180-190 Cr
+N/A
Existing plant order book for next year is completely booked with no spare reactor capacity.
ANLONHEALTHCARE
Healthcare
15 Feb 2026
Anlon Healthcare Ltd — Q3 FY26
Anlon Healthcare delivered a stellar Q3 FY26 with revenue surging to ₹35.78 Cr (up 281% YoY) and EBITDA margin of 35.06%, driven by higher API and intermediate volumes, operating leverage, and improved product mix.
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Anlon Healthcare delivered a stellar Q3 FY26 with revenue surging to ₹35.78 Cr (up 281% YoY) and EBITDA margin of 35.06%, driven by higher API and intermediate volumes, operating leverage, and improved product mix. PAT turned positive at ₹5.15 Cr vs a loss last year. Management guided for ~30% revenue CAGR over three years, with FY27 revenue of ₹370-380 Cr (conservative) supported by acquisitions of Epico Organics and Bizotic Life Sciences, which will add combined capacity of 1,400-1,600 MTPA. Key growth drivers include CDMO engagements (three molecules under validation), new API launches (7 in FY27), and expansion into peptides and formulations. Risks include high working capital days (currently ~290 days, target 150-160 by FY27) and execution risk in integrating acquisitions and greenfield capex of ₹100-120 Cr.
Key Numbers
Epico Order Book (FY27)
₹125-130 Cr
+N/A
Confirmed order book for Epico Organics for next financial year.
Combined Installed Capacity
1,400-1,600 MTPA
+250% vs current 400 MTPA
Post-acquisition of Epico and Bizotic, capacity expands significantly from current 400 MTPA.
Working Capital Days
~290 days
Target 150-160 days by FY27
Current receivable days high; management targets reduction through improved payment terms.
Management Guidance
FY27 Revenue Guidance of ₹370-380 Cr
Management expects consolidated revenue of ₹370-380 Cr for FY27, driven by existing operations and acquisitions, with potential upside.
Management guidance revenue30% Revenue CAGR Over Next 3 Years
Company targets approximately 30% revenue CAGR over the next three years, supported by capacity expansion and new product launches.
Management guidance growthBlended EBITDA Margin of 32-33%
Consolidated EBITDA margin expected to be 32-33% going forward, with Enlon at 35%+ and Epico at ~30%.
Management guidance marginsGreenfield Capex of ₹100-120 Cr
Company plans ₹100-120 Cr capex for greenfield expansion, funded by internal accruals (₹40-50 Cr) and bank debt (₹50-60 Cr), to be completed by March 2027.
Management guidance capexKey Risks
High Working Capital Days
Receivable days are currently ~290 days, posing cash flow risk. Management targets reduction to 150-160 days by FY27, but execution is uncertain.
high · analyst_questionIntegration and Execution Risk from Acquisitions
Acquisitions of Epico and Bizotic require smooth integration; any delays or operational issues could impact revenue and margin targets.
medium · management_commentaryCustomer Concentration in NSAID Segment
~30-35% revenue from loxoprofen and ketoprofen; any demand shock or regulatory issue in this segment could materially affect results.
medium · analyst_questionCapacity Constraints Before Greenfield Completion
Existing facilities are near full utilization; until greenfield expansion is operational (by March 2027), growth may be constrained.
medium · data_observationNotable Quotes
We are believing that result would be much better than 370 to 380 CR.
We are the only Indian manufacturer of loxoprofen and we'll have the first-mover advantage with monopoly in pain management.
In healthcare segment all the pharma company in India are almost at the same level... everyone is having equal opportunities.
Frequently Asked Questions
What was Anlon Healthcare's revenue in Q3 FY26?
Anlon Healthcare reported revenue of ₹36 Cr in Q3 FY26, representing a +281.45% change compared to the same quarter last year.
What guidance did Anlon Healthcare management give for FY27?
FY27 Revenue Guidance of ₹370-380 Cr: Management expects consolidated revenue of ₹370-380 Cr for FY27, driven by existing operations and acquisitions, with potential upside. 30% Revenue CAGR Over Next 3 Years: Company targets approximately 30% revenue CAGR over the next three years, supported by capacity expansion and new product launches. Blended EBITDA Margin of 32-33%: Consolidated EBITDA margin expected to be 32-33% going forward, with Enlon at 35%+ and Epico at ~30%. Greenfield Capex of ₹100-120 Cr: Company plans ₹100-120 Cr capex for greenfield expansion, funded by internal accruals (₹40-50 Cr) and bank debt (₹50-60 Cr), to be completed by March 2027.
What are the key risks for Anlon Healthcare in FY27?
Key risks include High Working Capital Days — Receivable days are currently ~290 days, posing cash flow risk. Management targets reduction to 150-160 days by FY27, but execution is uncertain.; Integration and Execution Risk from Acquisitions — Acquisitions of Epico and Bizotic require smooth integration; any delays or operational issues could impact revenue and margin targets.; Customer Concentration in NSAID Segment — ~30-35% revenue from loxoprofen and ketoprofen; any demand shock or regulatory issue in this segment could materially affect results.; Capacity Constraints Before Greenfield Completion — Existing facilities are near full utilization; until greenfield expansion is operational (by March 2027), growth may be constrained..
Did Anlon Healthcare meet its previous quarter's guidance?
Scorecard data is being built as historical quarters are processed.
Where can I read the full Anlon Healthcare Q3 FY26 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary with filing verification status shown on the financial stats.